User account menu Search Menu Shareholder Information Share Buy-Back Overview The shareholders of Novartis granted the current authorization to the Novartis Board to repurchase Novartis shares up to a maximum amount of CHF 10 billion via a second trading line on the SIX Swiss Exchange. Current Program Official notices in German, French and English Rückkauf eigener Aktien zum Zweck der Kapitalherabsetzung (PDF 0.2 MB) Rachat d’actions en vue d’une réduction du capital (PDF 0.2 MB) Buyback of own shares for the purpose of a capital reduction (PDF 0.2 MB) Novartis registered shares on the second line ISIN CH0038459415 Ticker NOVNEE Repurchases of Novartis shares are carried out on a second trading line on the SIX Swiss Exchange, with Novartis as the exclusive buyer. A shareholder wishing to sell Novartis shares may do so either via the ordinary trading line or via the second line. Novartis shares sold via the second trading line are subject to the Swiss federal withholding tax of 35% on half of the difference between the buyback price and the par value of the registered shares. Should Novartis not have any reserves from capital paid in (Kapitaleinlagereserven) left at its disposal before the end of the buyback program, the Swiss federal withholding tax will be raised on the full difference between the buyback price and the par value of the registered shares from this point on. Special cases remain reserved. The repurchasing company respectively the bank mandated by the company deducts the tax from the buyback price on behalf of the Swiss Federal Tax Administration. This withholding tax can be reclaimed by qualified investors. Transaction reporting Download reporting data (ZIP 0.1 MB) Maximum daily repurchase volume 2,409,537 shares (calculated in accordance with Art. 123(1)(c) of the Swiss Federal Financial Markets Infrastructure Ordinance) Closed Programs Resultat des Aktienrückkaufprogrammes vom 27. Februar 2017 bis 26. Februar 2020 (PDF 0.2 MB) Novartis Navigate Topics Explore Companies Footer Bottom © 2021 Novartis AG Terms of Use Privacy Contacts Cookie Settings Site Map Novartis Site Directory This site is intended for a global audience